Association Between GATA3 and Histopathological and Immunohistochemical Parameters in Early-Infiltrating Breast Carcinomas

Imagem de Miniatura
Arquivos
art_SOUZA_Association_Between_GATA3_and_Histopathological_and_Immunohistochemical_Parameters_2022.PDF (758.3 KB)
Citações na Scopus
2
Tipo de produção
article
Data de publicação
2022
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
GALENOS PUBL HOUSE
Autores
GAGLIATO, Debora
Citação
EUROPEAN JOURNAL OF BREAST HEALTH, v.18, n.3, p.229-234, 2022
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Objective: This study evaluated the frequency of GATA-binding protein 3 (GATA3) expression in early breast cancer and its relationship with histopathological and immunohistochemical parameters. Materials and Methods: GATA3 was analysed by immunohistochemistry in histological sections of rumors from 105 female patients, with histological diagnosis of invasive breast carcinoma (BC), at clinical stages I, II and IIIA, who underwent primary surgical treatment. GATA3 nuclear expression was determined as the percentage of positive tumor cells and further categorized as high (positive expression in more than 95% of cells) or non-high (negative or low positive expression in up to 95% of rumor cells). GATA3 expression was analysed according to the patient age, tumor and node pathological stage, histological type, histological and nuclear grade, lymphovascular invasion, and estrogen receptor (ER), progesterone receptor (PR), androgen receptor (AR), human epidermal growth factor 2 (HERZ) status, and Ki-67 expression. Results: GATA3 expression was positive in 103 cases (98.1%). High expression was significantly associated with low histological and nuclear grade, positive hormonal receptors, and less proliferative activity based on Ki-67 expression. A prominent feature was that 94.7% of the ER-posirive/HER2-negative cases presented high-GATA3 expression, as 94.0% of the rumors showing high-GATA3 were ER-positive. In ER-negative/HER2-positive or ER-negative/HER2- negative, high-GATA3 was present in 25% while 75% were non-high-GATA3 compared with ER-positive/HER2- negative (4.1%) and ER-positive/HER2-positive (20%). Proliferative activity in triple-negative breast cancer tended to be higher among rumors with low-GKIA3, irrespective of AR expression. In the group of ER-positive/HER2-negative tumors only three cases were low-GATA3 (85% and 80%), both with high proliferative activity. Conclusion: High GATA3 expression is associated with favorable histopathologic and immunohistochemical BC prognostic factors.
Palavras-chave
Breast cancer, GATA3 expression, immunohistachemistry, histopathology
URI
https://observatorio.fm.usp.br/handle/OPI/48582
Referências
  1. Cakir A, 2017, PATHOL RES PRACT, V213, P227, DOI 10.1016/j.prp.2016.12.010
  2. Cimino-Mathews A, 2021, MODERN PATHOL, V34, P62, DOI 10.1038/s41379-020-00697-3
  3. Gonzalez RS, 2013, HUM PATHOL, V44, P1065, DOI 10.1016/j.humpath.2012.09.010
  4. Husni Cangara M, 2021, Breast Dis, V40, pS27, DOI 10.3233/BD-219004
  5. Kouros-Mehr H, 2006, CELL, V127, P1041, DOI 10.1016/j.cell.2006.09.048
  6. Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014
  7. Liu XY, 2018, THERANOSTICS, V8, P6386, DOI 10.7150/thno.29164
  8. Lopez G, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030510
  9. Lu SL, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-6295-8
  10. Mehra R, 2005, CANCER RES, V65, P11259, DOI 10.1158/0008-5472.CAN-05-2495
  11. Midha MK, 2020, CANCERS, V12, DOI 10.3390/cancers12082089
  12. Min KW, 2016, VIRCHOWS ARCH, V468, P409, DOI 10.1007/s00428-015-1894-5
  13. Najafabadi MK, 2021, PATHOL RES PRACT, V226, DOI 10.1016/j.prp.2021.153611
  14. Parikh P, 2005, J AM COLL SURGEONS, V200, P705, DOI 10.1016/j.jamcollsurg.2004.12.025
  15. Poon IK, 2020, BRIT J CANCER, V123, P1223, DOI 10.1038/s41416-020-1009-1
  16. Querzoli P, 2021, DIAGNOSTICS, V11, DOI 10.3390/diagnostics11040604
  17. Schrodi S, 2021, ANN ONCOL, V32, P1410, DOI 10.1016/j.annonc.2021.08.1988
  18. Tahiri A, 2020, BREAST CANCER RES TR, V183, P585, DOI 10.1007/s10549-020-05763-7
  19. Takaku M, 2020, NUCLEIC ACIDS RES, V48, P4756, DOI 10.1093/nar/gkaa179
  20. Takaku M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03478-4
  21. Takaku M, 2015, GENE EXPRESSION, V16, P163, DOI 10.3727/105221615X14399878166113
  22. WHO Classification of Tumours Editorial Board, 2019, WHO CLASS TUM ED BOA
  23. Yildirim E, 2020, ANTICANCER RES, V40, P5649, DOI 10.21873/anticanres.14578
  24. Yoon NK, 2010, HUM PATHOL, V41, P1794, DOI 10.1016/j.humpath.2010.06.010
  25. Yu S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40811-3

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - ODS/03